SmartCells

SmartCells, Inc. is a biotechnology company founded in 2003 with a focus on developing innovative solutions for diabetes and other medical applications. The company's flagship product, SmartInsulin, is a self-regulating injectable insulin formulation designed to improve diabetes management. In addition to diabetes, SmartCells' advanced polymer-based dosing technology has potential applications in addressing a variety of medical needs, including fertility, thyroid, and growth hormone deficiencies. The company also seeks to tackle challenges in treatment compliance and therapeutic window issues in areas such as oncology and drug-device combinations. SmartCells, Inc. received a significant $4.10M Series D investment on 16 June 2010, with funding contributed by notable investors including Beacon Angels, Boston Harbor Angels, Cherrystone Angel Group, Angel Healthcare Investors, and CVP Management. The company, headquartered in Beverly, Massachusetts, continues to demonstrate potential for growth and impact in the biotechnology and healthcare industries. With its focus on addressing critical medical needs and its track record of attracting investments from respected angel and venture capital groups, SmartCells, Inc. stands as a compelling player in the evolving landscape of medical innovation and treatments.